(0)
Novel mucoadhesive patch adheres to wet tissue surfaces and enables targeted, localized delivery of therapeutic to lesions inside the mouth AFYX Therapeutics ( AFYX ), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that a study of the Rivelin Clobetasol patch ( Rivelin-CLO ), a novel adhesive patch technology designed to deliver a therapeutic agent to wet tissue surfaces, was featured in the March issue of
The European Journal of Oral Sciences. This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.